摘要
目的 观察异环磷酰胺、鬼臼乙叉甙、卡铂 (IEC)方案治疗晚期非小细胞肺癌的疗效和毒副反应。方法 3 3例晚期非小细胞肺癌患者接受IEC方案化疗。观察全组患者的近、远期疗效及毒副反应。结果 全组患者PR 7例 ,NC 2 4例 ,PD 2例 ,有效率为 2 1.2 % (7/3 3 ,95 %CI :7.3 %~ 3 5 .1% ) ;中位生存期 7.8月(95 %CI :6.2~ 9.4月 ) ;1年生存率为 2 0 .0 % (95 %CI :6.0 %~ 3 4.0 % )。主要毒副反应为较严重的血液学毒性 ,Ⅲ~Ⅳ度白细胞减少、血小板减少及血红蛋白减少发生率分别为 5 1.5 % (17/3 3 )、18.2 % (6/3 3 )和 3 0 .3 %(10 /3 3 )。 60岁以上组Ⅲ~Ⅳ度白细胞减少发生率 (P =0 .0 2 4)和血小板减少发生率 (P =0 .0 3 7)明显高于 60岁以下组。结论 IEC方案对晚期非小细胞肺癌有效 ;主要毒副反应为较严重的血液学毒性 ,尤其高发于老年人 ,因此对于老年患者最好在G CSF或GM
Objective To investigate the efficacy and toxicity of ifosfamide, etoposide, and carboplatin (IEC) regimen in the treatment of patients with advanced non small cell lung cancer. Methods Thirty three patients with advanced non small cell lung cancer were treated with IEC regimen, which consisted of ifosfamide 2.0?g/m 2(patients with age>70 years: 1.3?g/m 2), IV D1 3; etoposide 130?mg/m 2, IV D1 3; carboplatin 300?mg/m 2, IV D1, repeated every four weeks. Results Of the 33 patients, 7 cases got partial response, 24 had stable diseases, and 2 had progressive diseases, and the overall response rate was 21.2% (7/33,95% CI: 7.3% to 35.1%). The median survival and 1 year survival rate were 7.8 months (95% CI: 6.2 to 9.4 months) and 20.0%(95% CI: 6.0% to 34.0%) respectively. Main adverse effects were severe hematologic toxicities. The frequency of leukopenia,thrombocytopenia and anemia with grade Ⅲ and grade Ⅳ was 51.5% (17/33), 18.2%(6/33) and 30.3%(10/33) respectively. There was significantly higher frequency of leukopenia (P=0.024) and thrombocytopenia (P=0.037) with grade Ⅲ and grade Ⅳ in patients with age≥60 years than those with age <60 years. Conclusion IEC is an effective regimen in the treatment of patients with advanced non small cell lung cancer. Main adverse effects are severe hematologic toxicities, which are more significant in elderly patients. It is necessary to apply G CSF or GM CSF protection to avoid severe myelosuppression for elderly patients.
出处
《中国肺癌杂志》
CAS
2002年第3期198-200,共3页
Chinese Journal of Lung Cancer